Abstract
Telik Inc is developing TLK-286, a modified glutathione analog prodrug, for the potential treatment of cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 771-781 |
| Number of pages | 11 |
| Journal | IDrugs |
| Volume | 7 |
| Issue number | 8 |
| State | Published - Aug 2004 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
ASJC Scopus subject areas
- Pharmacology
- Drug Discovery
Fingerprint
Dive into the research topics of 'TLK-286'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS